Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. This news page aggregates company press releases, clinical updates, financial disclosures, and corporate announcements so readers can follow how Fate Therapeutics’ iPSC-derived CAR T-cell and NK-cell programs progress over time.
Recent news from Fate Therapeutics has highlighted updated Phase 1 clinical data for FT819, its off-the-shelf CD19-targeted CAR T-cell product candidate for systemic lupus erythematosus (SLE), including reports of sustained reductions in disease activity scores, B-cell depletion with immune remodeling, and a favorable safety profile with less-intensive or no conditioning chemotherapy. The company has also issued news on regulatory authorizations to expand FT819 trials into the United Kingdom and European Union, initiation of dose-expansion cohorts in additional autoimmune diseases, and presentations at major medical meetings such as the American College of Rheumatology (ACR) Convergence and the American Society of Hematology (ASH) Annual Meeting.
In oncology, Fate Therapeutics’ news flow includes updates on FT825 / ONO-8250 for advanced HER2-positive solid tumors and FT836, a MICA/B-targeted CAR T-cell program being evaluated without conditioning chemotherapy, as well as preclinical progress on FT839, a dual CAR T-cell candidate co-targeting CD19 and CD38. Investors can also find quarterly financial results, details of corporate restructuring to streamline operations and extend cash runway, and information on executive appointments and employee inducement equity awards.
By reviewing the FATE news feed, readers can track clinical milestones, regulatory interactions, conference presentations, and corporate developments that shape the company’s iPSC-derived cell therapy pipeline. Bookmark this page for a consolidated view of Fate Therapeutics’ latest publicly released information.
Fate Therapeutics (NASDAQ: FATE) granted 7,260 restricted stock units (RSUs) on April 1, 2026 to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved the award under the companys Amended and Restated Inducement Equity Plan.
The RSUs vest over four years with 25% vesting on each anniversary, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) granted restricted stock units representing 50,700 shares to three newly hired non-executive employees on March 2, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The awards vest over four years with 25% vesting on each anniversary, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.
Fate Therapeutics (NASDAQ: FATE) reported Q4 and full-year 2025 results and clinical progress on Feb 26, 2026. The company ended 2025 with $205.1 million in cash, projects runway through year-end 2027, and recorded Q4 revenue of $1.4 million. FT819 achieved outpatient dosing across autoimmune indications (15 SLE, 4 SSc, 1 IIM treated) and showed a 3-month improvement in a systemic sclerosis patient. FT836 showed a >50% CEA reduction in a CRC patient without conditioning chemotherapy. Operating expenses declined ~30% in 2025 versus 2024.
Fate Therapeutics (NASDAQ: FATE) granted inducement awards on February 1, 2026 to a newly-hired non-executive employee under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The package includes 120,000 non-qualified stock options at an exercise price of $1.19 per share and 90,000 restricted stock units (RSUs). Options vest over four years (25% at one year, remainder monthly over 36 months); RSUs vest 25% each anniversary over four years, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) announced inducement equity awards granted on January 1, 2026 to newly hired non-executive employees under its Amended and Restated Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The company granted a non-qualified stock option for 48,000 shares at an exercise price of $0.98 (NASDAQ close on December 31, 2025) to one new hire and 79,400 restricted stock units (RSUs) to four new hires (one individual received both the option and RSUs). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over four years with 25% vesting on each anniversary, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) presented updated Phase 1 data for off-the-shelf CAR T candidate FT819 and preclinical advances for FT836 and FT839 at ASH 2025. 13 patients enrolled (12 SLE, 1 SSc); 10 SLE patients had ≥1 month follow-up. FT819 showed progressive mean SLEDAI-2K score reductions (DL1: 50% at 3 months, 70% at 6 months; DL2: 65% at 3 months, 78% at 6 months [n=1 at 6 months]), durable B‑cell depletion, meaningful FACIT‑fatigue improvements, no Grade >2 CRS/ICANS/GVHD, and on‑demand dosing from inventory. Company plans to discuss a registrational trial for FT819 in 2026 under RMAT. Preclinical FT836/FT839 data show expanded antigen targeting and conditioning‑free approaches for hematologic and autoimmune indications.
Fate Therapeutics (NASDAQ: FATE) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.
A live webcast of each presentation, if recorded, will be accessible under “Events & Presentations” in the Investors section at www.fatetherapeutics.com, and archived webcasts will be posted on the company website shortly after the event.
Fate Therapeutics (NASDAQ: FATE) reported Q3 2025 results and program updates on Nov 13, 2025. Key clinical progress includes MHRA and EMA authorization to open ex-US FT819 sites and updated Phase 1 FT819 data showing meaningful SLEDAI-2K score reductions (mean −10.7 at 3 months, −14 at 6 months in Regimen A) with no dose-limiting toxicities, no ICANS or GvHD, and only low-grade CRS. First systemic sclerosis patient treated with fludarabine-free conditioning; first FT836 solid tumor patient treated without conditioning. Financials: $225.7M cash (Sept 30, 2025), Q3 revenue $1.7M, and Q3 operating expenses $36.5M; company projects runway through year-end 2027 with $226M in cash, cash equivalents, and investments.
Fate Therapeutics (NASDAQ: FATE) announced on November 1, 2025 that it granted restricted stock units representing 34,700 shares to three newly hired non-executive employees as inducement awards under its Amended and Restated Inducement Equity Plan.
The grants were approved by the Compensation Committee and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.